
Description: Acne vulgaris is a common chronic inflammatory skin disease which normally takes place in the adolescence stage on one's life, closer to puberty. Although acne vulgaris is a skin disease, its onset in teenagers often affects their wellbeing because of the physical changes which take place because of the disease. There are a number of factors which lead to acne vulgaris, of which the four primary factors are excessive sebum production, bacterial growth and colonization, sloughing of keratinocytes and inflammation and immune system response. The lesions which are formed from acne vulgaris can often remain as a scar for the greater part of an individual's life.

One of the key trends observed in the acne vulgaris treatment market is the use of a combination of products for the treatment such as Ziana and Duac. There are a number of products which are available in the market for the treatment of acne vulgaris, however, not all have been found to be suitable for treatment purposes. There have been cases where certain anti-acne products have caused blood clots due to prolonged use. Such products were banned by the medical associations of the respective countries. The initial and only products which were available for acne vulgaris treatment were various types of creams. Today however, there are alternative treatments such as the use of UV and infrared lights which can be provided by numerous clinics. Another key trend in the market has been the setting up of specific skin clinics for various skin conditions of which acne vulgaris is the most common of the lot.

In terms of geographical distribution, the acne vulgaris market for treatment is dominated by North America further to which it is found to be a common disease in the US particularly. It is estimated that more than 60 million individuals are affected by acne vulgaris in the US. Following North America, Europe is the next largest market for acne vulgaris treatment. The APAC region has just come into the limelight with respect to cosmetic treatments. In this view, the APAC market presents the biggest potential for acne vulgaris companies to penetrate. Emerging economies in the region present the best potential for cosmetic-related treatments, especially countries such as India and China.

In terms of treatment the Acne Vulgaris market has been divided into the following Adapalene, Tazaroteen, Tretinoin and Isotretinoin, Erythromycin and Clindamycin, Hormonal agents, combination medications, anti-inflammatory, Azelaic acid, Resorcinol, laser and light therapy, cosmetic procedures and acne scar treatments. The Acne vulgaris market has also been segmented by the following geographies Americas, APAC, Europe and ROW.

Following are just a few of the companies that are operating in the Acne vulgaris market:
Allergan
Bayer AG
Cipher
Galderma S.A
Hygeia Laboratories Inc
Johnson & Johnson Private Limited.
Stiefel Laboratories
Valeant Pharmaceutical International Inc.

Contents:
1. Acne Vulgaris- Market Overview
2. Executive Summary
3. Acne Vulgaris - Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Acne Vulgaris- Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Acne Vulgaris Market
  4.4.1. Power of Suppliers
  4.4.2. Power of Customers
  4.4.3. Threat of New Entrants
  4.4.4. Threat of Substitution
  4.4.5. Degree of Competition
5. Acne Vulgaris - Strategic Analysis
  5.1. Value Chain Analysis
  5.2. Pricing Analysis
  5.3. Opportunities Analysis
  5.4. Market Life Cycle Analysis
  5.5. Suppliers and Distributors
6. Acne Vulgaris Market - By Treatment
  6.1. Adapalene
  6.2. Tazaroteen
  6.3. Tretinoin
  6.4. Isotretinoin
  6.5. Erythromycin
  6.6. Clindamycin
  6.7. Hormonal agents
  6.8. Combination medications
  6.9. Anti-inflammatory
  6.10. Azelaic acid
  6.11. Resorcinol
  6.12. Laser and light therapy
  6.13. Cosmetic procedures
7. Acne Vulgaris Market- By Geography:
  7.1. Global Study
  7.2. Americas
    7.2.1. North America
    7.2.2. Brazil
    7.2.3. Argentina
    7.2.4. Others
  7.3. Europe
    7.3.1. U.K.
    7.3.2. France
    7.3.3. Germany
    7.3.4. Others
  7.4. APAC
    7.4.1. China
    7.4.2. Japan
    7.4.3. India
    7.4.4. Others
  7.5. ROW
8. Market Entropy
  8.1. New Product Launches
  8.2. M&As, Collaborations, JVs and Partnerships
9. Company Profiles
  9.1. Allergan
  9.2. Bayer AG
  9.3. Cipher
  9.4. Galderma S.A
  9.5. Hygeia Laboratories Inc
  9.7. Stiefel Laboratories
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
**Financials would be provided on a best efforts basis for private companies**
10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Bibliography
10.5. Compilation of Expert Insights
10.6. Disclaimer

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3820840/](http://www.researchandmarkets.com/reports/3820840/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/3820840/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

**Quantity**

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td></td>
<td>USD 4725</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>USD 5250 - Until May 31st 2017</strong></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 5625</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>USD 6250 - Until May 31st 2017</strong></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 7605</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>USD 8450 - Until May 31st 2017</strong></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ___________________  Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐
First Name: ___________________  Last Name: ___________________
Email Address: * ___________________
Job Title: ___________________
Organisation: ___________________
Address: ___________________
City: ___________________
Postal / Zip Code: ___________________
Country: ___________________
Phone Number: ___________________
Fax Number: ___________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World